{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:00Z","timestamp":1793963040445,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and\/or microcyst-like epithelial changes (MECs), eye examination findings with\/without symptoms), were common, consistent with reports from other antibody\u2013drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology\/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist\/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit\u2013risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.<\/jats:p>","DOI":"10.1038\/s41408-021-00494-4","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T13:03:14Z","timestamp":1622034194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneetha","family":"Thulasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Z.","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennie H.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Opalinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Piontek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V.","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Colby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-6822","authenticated-orcid":false,"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"494_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clml.2016.11.010","volume":"17","author":"A Agarwal","year":"2017","unstructured":"Agarwal A. et al. Practical considerations in managing relapsed multiple myeloma. Clin. Lymphoma Myeloma Leuk. 17, 69\u201377 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"494_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael, J. Treatment options for triple-class refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 20, 1\u20137 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"494_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai, Y. T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7, 1187\u20131199 (2015).","journal-title":"Immunotherapy"},{"key":"494_CR4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi, U. H. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275 (2019).","journal-title":"Leukemia"},{"key":"494_CR5","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128\u20133138 (2014).","journal-title":"Blood"},{"key":"494_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/01.HS9.0000560524.63281.bc","volume":"3","author":"R Montes De Oca","year":"2019","unstructured":"Montes De Oca, R. et al. PF558 The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity. HemaSphere 3, S1 (2019).","journal-title":"HemaSphere"},{"key":"494_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"494_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"494_CR9","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1200\/JCO.2020.38.15_suppl.8536","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs). J. Clin. Oncol. 38, 8536 (2020).","journal-title":"J. Clin. Oncol."},{"key":"494_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/bs.pmbts.2015.04.001","volume":"134","author":"AO Eghrari","year":"2015","unstructured":"Eghrari, A. O., Riazuddin, S. A. & Gottsch, J. D. Overview of the cornea: structure, function, and development. Prog. Mol. Biol. Transl. Sci 134, 7\u201323 (2015).","journal-title":"Prog. Mol. Biol. Transl. Sci"},{"key":"494_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq, A. V. et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol. Ther. 9, 889\u2013911 (2020).","journal-title":"Ophthalmol. Ther."},{"key":"494_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy, H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8, 659\u2013671 (2016).","journal-title":"MAbs"},{"key":"494_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton, J. S., Miller, P. E., Mannis, M. J. & Murphy, C. J. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31, 589\u2013604 (2015).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"494_CR14","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.3390\/hematolrep12120001","volume":"12","author":"AD Cohen","year":"2020","unstructured":"Cohen, A. D. et al. Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; GSK2857916) treatment in DREAMM-2 study: 13-month follow-up: session: multiple myeloma. Hematol. Rep. 12, s1 (2020).","journal-title":"Hematol. Rep."},{"key":"494_CR15","doi-asserted-by":"crossref","unstructured":"Lonial, S. et al. Recovery of ocular events with longer-term follow-up in the DREAMMM-2 study of single-agent belantamab mafodotin (belamaf) in patients with relapsed or refractory multiple myeloma (RRMM). Presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology, abstr. 3224 (2020).","DOI":"10.1182\/blood-2020-140078"},{"key":"494_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","volume":"28","author":"J Antoun","year":"2016","unstructured":"Antoun, J., Titah, C. & Cochereau, I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr. Opin. Oncol. 28, 288\u2013294 (2016).","journal-title":"Curr. Opin. Oncol."},{"key":"494_CR17","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling, L. et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4, e000491 (2019).","journal-title":"ESMO Open"},{"key":"494_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","volume":"50","author":"O Huillard","year":"2014","unstructured":"Huillard, O. et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur. J. Cancer 50, 638\u2013648 (2014).","journal-title":"Eur. J. Cancer"},{"key":"494_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4321\/S1885-642X2006000200001","volume":"4","author":"AE Omoti","year":"2006","unstructured":"Omoti, A. E. & Omoti, C. E. Ocular toxicity of systemic anticancer chemotherapy. Pharm. Pract. (Granada) 4, 55\u201359 (2006).","journal-title":"Pharm. Pract. (Granada)"},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-030-41008-7_17","volume":"1244","author":"A Srivastava","year":"2020","unstructured":"Srivastava, A. et al. Immune-related oral, otologic, and ocular adverse events. Adv. Exp. Med. Biol. 1244, 295\u2013307 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"494_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17474086.2020.1728248","volume":"13","author":"B Gatta","year":"2020","unstructured":"Gatta, B. & LeBlanc, T. W. Palliative care in hematologic malignancies: a multidisciplinary approach. Expert Rev. Hematol. 13, 223\u2013231 (2020).","journal-title":"Expert Rev. Hematol."},{"key":"494_CR22","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","volume":"105","author":"R Popat","year":"2020","unstructured":"Popat, R. et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica 105, e261\u2013e263 (2020).","journal-title":"Haematologica"},{"key":"494_CR23","unstructured":"GlaxoSmithKline Research Triangle Park, NC. BLENREP [package insert]. https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF (2020)."},{"key":"494_CR24","unstructured":"GlaxoSmithKline (Ireland) Limited. BLENREP SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf. (2020)."},{"key":"494_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/diagnostics10080589","volume":"10","author":"D Schmidl","year":"2020","unstructured":"Schmidl, D., Schlatter, A., Chua, J., Tan, B. & Garh\u00f6fer, G. Novel approaches for imaging-based diagnosis of ocular surface disease. Diagnostics 10, 589 (2020).","journal-title":"Diagnostics"},{"key":"494_CR26","unstructured":"NIH National Eye Institute. Get a Dilated Eye Exam. Updated 2019. https:\/\/www.nei.nih.gov\/learn-about-eye-health\/healthy-vision\/get-dilated-eye-exam. (2020)"},{"key":"494_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/opo.12310","volume":"36","author":"DB Elliott","year":"2016","unstructured":"Elliott, D. B. The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement. Ophthalmic Physiol. Opt. 36, 355\u2013358 (2016).","journal-title":"Ophthalmic Physiol. Opt."},{"key":"494_CR28","unstructured":"Kolker, R. J. & Kolker, A. F. Subjective refraction and prescribing glasses: the number one (or number two) guide to practical techniques and principles 3rd edn (SLACK Incorporated, 2018)."},{"key":"494_CR29","unstructured":"Azzam, D. & Ronquillo, Y. Snellen Chart. [Updated 2020 Jun 10]. In: StatPearls [Internet] (StatPearls Publishing, 2020). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558961\/."},{"key":"494_CR30","unstructured":"Shipra, G., Pankaj, G., Rony, S. Healing a persistent corneal epithelial defect 2014. https:\/\/www.aao.org\/eyenet\/article\/healing-persistent-corneal-epithelial-defect. (2020)"},{"key":"494_CR31","unstructured":"Lee, S., Mesfin, F. B. Blindness. [Updated 2020 Aug 11]. In: StatPearls [Internet] (StatPearls Publishing, 2020) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448182\/."},{"key":"494_CR32","doi-asserted-by":"publisher","first-page":"704946","DOI":"10.1155\/2015\/704946","volume":"2015","author":"SP Phadatare","year":"2015","unstructured":"Phadatare, S. P., Momin, M., Nighojkar, P., Askarkar, S. & Singh, K. K. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges. Adv. Pharmaceutics 2015, 704946 (2015).","journal-title":"Adv. Pharmaceutics"},{"key":"494_CR33","first-page":"163","volume":"8","author":"U Vaidyanathan","year":"2019","unstructured":"Vaidyanathan, U. et al. Persistent corneal epithelial defects: a review article. Med. Hypothesis Discov. Innov. Ophthalmol. 8, 163\u2013176 (2019).","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"494_CR34","unstructured":"GlaxoSmithKline Research Triangle Park, NC. BLENREP Risk Evaluation and Mitigation Strategy (REMS). https:\/\/www.blenreprems.com (2020)."},{"key":"494_CR35","unstructured":"GlaxoSmithKline (Ireland) Limited. BLENREP Risk Management Plan (RMP). https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/blenrep-epar-risk-management-plan-summary_en.pdf (2020)."},{"key":"494_CR36","first-page":"193","volume":"12","author":"F Alipour","year":"2017","unstructured":"Alipour, F., Khaheshi, S., Soleimanzadeh, M., Heidarzadeh, S. & Heydarzadeh, S. Contact lens-related complications: a review. J. Ophthalmic Vis. Res. 12, 193\u2013204 (2017).","journal-title":"J. Ophthalmic Vis. Res."},{"key":"494_CR37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir, N. M. et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest. New Drugs 32, 1246\u20131257 (2014).","journal-title":"Invest. New Drugs"},{"key":"494_CR38","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/neuonc\/nox202","volume":"20","author":"HK Gan","year":"2018","unstructured":"Gan, H. K. et al. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro. Oncol. 20, 838\u2013847 (2018).","journal-title":"Neuro. Oncol."},{"key":"494_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/neuonc\/noy091","volume":"21","author":"AB Lassman","year":"2019","unstructured":"Lassman, A. B. et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro. Oncol. 21, 106\u2013114 (2019).","journal-title":"Neuro. Oncol."},{"key":"494_CR40","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","volume":"80","author":"M van den Bent","year":"2017","unstructured":"van den Bent, M. et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother. Pharmacol. 80, 1209\u20131217 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"494_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124\u20131235 (2019).","journal-title":"Lancet Oncol."},{"key":"494_CR42","doi-asserted-by":"crossref","unstructured":"Sonneveld, P. Management of multiple myeloma in the relapsed\/refractory patient. Hematol. Am. Soc. Hematol. Educ. Program 2017, 508\u2013517 (2017).","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"494_CR43","doi-asserted-by":"crossref","unstructured":"Brady, F. G. et al. Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed\/refractory multiple myeloma (RRMM): application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses. Proceedings of the 111th Annual Meeting of the American Association for Cancer Research, abstr. CT196 (2020).","DOI":"10.1158\/1538-7445.AM2020-CT196"},{"key":"494_CR44","doi-asserted-by":"crossref","unstructured":"Richardson, P. et al. DREAMM-5 platform trial: Belantamab mafodotin (belamaf) in combination with four different novel agents in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology, abstr. 2299 (2020).","DOI":"10.1182\/blood-2020-139182"},{"key":"494_CR45","doi-asserted-by":"crossref","unstructured":"Trudel, S. et al. DREAMM-8: a Phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) Vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology, abstr. 2302 (2020).","DOI":"10.1182\/blood-2020-139785"},{"key":"494_CR46","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","volume":"38","author":"A Nooka","year":"2020","unstructured":"Nooka, A. et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol 38, 8502 (2020).","journal-title":"J. Clin. Oncol"},{"key":"494_CR47","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.3390\/hematolrep12120001","volume":"12","author":"A Nooka","year":"2020","unstructured":"Nooka, A. et al. DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma. Hematol. Rep. 12, s1 (2020).","journal-title":"Hematol. Rep."},{"key":"494_CR48","unstructured":"Trudel, S. et al. Part 1 results of a dose finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide (POM) and dexamethasone (DEX) for the treatment of relapsed\/refractory multiple myeloma (RRMM). Presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology, abstr. 725 (2020)."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00494-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T12:27:26Z","timestamp":1672230446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00494-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00494-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L has received grant funding and personal fees from Celgene and Takeda, and personal fees from Novartis, Bristol-Myers Squibb, GSK, Amgen, Merck, and Janssen; A.K.N. has received grant funding and personal fees from GSK, Janssen, Bristol-Myers Squibb, Celgene, Takeda, and Amgen; and personal fees from Oncopeptides and Spectrum; B.H.J. has received compensation from GSK as a consultant; H.A.P. has received funding from the National Eye Institute and the Research to Prevent Blindness organization; D.S. has received personal fees from Celgene, Janssen, and Amgen; B.E.Z. consulted for and received honoraria from GSK; R.P. has received grant funding, personal fees, and non-financial support from Takeda; personal fees and non-financial support from Janssen, Celgene, and GSK, and personal fees from AbbVie; and support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre; S.D.E. has received personal fees from GSK; J.By. is an employee of and hold stocks and shares in GSK and hold stocks and share in Adaptimmune and Novartis; J.O., J.Ba., and T.P. are employees of and hold stocks and shares in GSK; I.G. is an employee of and holds stocks and shares in GSK and holds stocks and shares in Novartis; R.D. is a consultant for GSK, Domp\u00e9, Novartis, Alcon, and Kala; has ownership in Aramis Biosciences, Claris Biotherapeutics, and GelMEDIX; and has received funding from the NIH, DOD, and Allergan; A.V.F. is a consultant for GSK; K.C. is a consultant for GSK; A.J. consulted for and received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Juno, and Karyopharm; P.T., A.Z.B., and N.S.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"103"}}